SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001367644-23-000021
Filing Date
2023-02-15
Accepted
2023-02-15 07:06:24
Documents
17
Period of Report
2023-02-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20230215.htm   iXBRL 8-K 42853
2 EX-99.1 privconf_ebsemeraldrelea.htm EX-99.1 10257
6 privconf_ebsemeraldrelea001.jpg GRAPHIC 213573
7 privconf_ebsemeraldrelea002.jpg GRAPHIC 205630
8 privconf_ebsemeraldrelea003.jpg GRAPHIC 213124
9 privconf_ebsemeraldrelea004.jpg GRAPHIC 25890
  Complete submission text file 0001367644-23-000021.txt   1108872

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20230215.xsd EX-101.SCH 1965
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20230215_lab.xml EX-101.LAB 25154
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20230215_pre.xml EX-101.PRE 13100
11 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20230215_htm.xml XML 11453
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

IRS No.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 23633591
SIC: 2834 Pharmaceutical Preparations